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Introduction to the National Institute for Health
Research
In 2006, the Department of Health formed the National
Institute of Health Research (NIHR) to create an environ-
ment for world class health research within the National
Health Service (NHS). Historically, research occurred
mainly in teaching hospitals, with a lack of equal opportunity
for patients to participate in research and no overall
nationwide framework to assist the conduct of research
within theNHS.With themission to ‘Improve the health and
wealth of the nation through research’, the NIHR has
transformed clinical research in the United Kingdom
through the establishment of the hugely successful Clinical
Research Network (CRN) and the initiation of a national
portfolio of studies, together providing the local infrastruc-
ture to support clinical researchers in conducting high-
quality research. This has led to an increased number of
healthcare professionals and patients participating in
research and the NHS being seen as an international leader
in clinical research.
What is the NIHR?
• TheNational Institute forHealth Research is a national
organisation operating within the NHS with the
mission to improve the health and wealth of the
nation through research
• It is led by the Chief Medical Officer Professor Dame
Sally Davis
• The overall annual budget is ring-fenced at 1% of the
NHS budget (£1 billion)
Academics, clinicians, industries and patients involved in
ENT clinical research may already be aware of the CRN and
the support they offer for the delivery of research. Equally,
the CRN may be viewed by some as a familiar name, but a
vast and complex organisation of unknown capacity. Or
possibly, the CRN is a completely unknown entity. This brief
paper aimed to provide practical information to enable ENT,
hearing and balance specialties to benefit from the research
infrastructural support provided by the CRN. We will focus
on the impact the network has had on recent ENT studies as
well as an introduction to the recognisable names behind the
network and the support it offers.
What is the Clinical Research Network?
• The CRN was set up by the NIHR to enable NHS
patients and health professionals across England to
participate in high-quality relevant clinical research
• The annual budget for the CRN is £286 m
• The CRN provides a unique health service infrastruc-
ture to support clinical research in the NHS
Where does ENT fit in the structure of the NIHR Clinical
Research Network?
The CRN comprises of 15 Local Clinical Research Networks
(LCRNs) that cover the length and breadth of England
(Fig. 1). Each LCRN delivers research across 30 clinical
specialties including ENT. A national coordinating centre
provides central management for the network. Similar
system exists within the devolved nations and details
regarding those can be found at: http://www.cso.scot.nhs.
uk/, http://www.nicrn.hscni.net/ and http://www.wales.nhs.
uk/sites3/home.cfm?orgid=952.
The NIHR CRN Portfolio, what is it and what are the
benefits?
At the heart of the CRN’s activities is the NIHR CRN
Portfolio. This consists of high-quality clinical research
studies that are eligible for consideration for support from
the CRN in England.
The portfolio database captures research activity data and
provides analysis tools to facilitate active management of
current studies, and the feasibility of future studies run
within the CRN. Activity data from the portfolio are used to
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inform the allocation of NHS infrastructure for research
(includingNHS support costs) and support the performance
management of the CRN.
There have been over 90 observational and interventional
Ear, Nose and Throat studies registered on the portfolio as it
was set up and over 30 of these are currently recruiting
participants within the NHS (http://public.ukcrn.org.uk/
search/). Clinical studies registered on the portfolio benefit
from the CRN infrastructure that has been put in place to
assist researchers to complete their research, including the
following:
• Access to a local network of dedicated skilled research
support staff including research nurses and other allied
health professionals, who can help identify eligible
patients, arrange consent to participate in the study
and monitor patients as they progress through the
study
• Support to ensure that a given study can be successfully
undertaken in theNHS including pharmacy, imaging and
pathology services and the possibility of securing pro-
tected time for NHS staff to conduct research
• Provision of dedicated systems to assist researchers in
gaining approvals to open their studies within the NHS
quickly and efficiently (Coordinated System of Permis-
sions, CSP). In the past, researchers had to make separate
permission applications to every trust, but the CRN has
revolutionised this process through CSP. Researchers
now only enter their study details once, even on multisite
studies. The CRN then coordinates all the necessary NHS
Research and Development reviews at every participating
NHS Trust through CSP.
• Practical help in identifying and recruiting patients onto
portfolio studies, so that researchers can be confident of
completing the study on time and with the target number
of participants required.
• National monitoring of the monthly performance of
portfolio studies and the availability of local dedicated
ENT, hearing and balance experts to assist with specialist
knowledge to help recruit participants to studies
(Table 1).
All researchers with funded ENT research projects
should therefore consider applying for portfolio inclusion
to gain advantage of this support the CRN offers and
bring this additional funding for research delivery into
their trust.
How can i get my ENT study adopted onto the
portfolio?
Both non-commercial (researcher-led) and commercial
(industry-led) studies can register to be included in the
portfolio. As the CRN is a government funded organi-
sation, all studies in England must comply with the
Department of Health established eligibility criteria for
commercial and non-commercial research to qualify for
CRN support.
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Fig. 1. NIHR Local Clinical Research Networks in England.
Table 1. Who is my ENT specialty local lead? Who can I contact for specialist advice?
Local clinical research network (LCRN) ENT specialty local lead Specialism
East Midlands Professor Deborah Hall Audiology
Eastern Mr Carl Philpott Rhinology, Anterior skull base
Greater Manchester Mr Kevin Green Otology
North East and North Cumbria Mr Anirvan Banerjee Otology
North Thames Professor Anne Schilder Paediatric ENT, Clinical trials methodology
North West Coast Mr Adam Donne Paediatric ENT
North West London Mr Taran Tatla Laryngology, Head and neck
Scotland Mr Kenneth MacKenzie Laryngology
South London Ms Claire Hopkins Rhinology, Anterior skull base
Thames Valley and South Midlands Mr James Ramsden Otology, Paediatric ENT
Yorkshire and Humber Mr Jaydip Ray Otology, Paediatric ENT
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Non-commercial studies
Eligibility for inclusion is judged by experts within the
CRN to ensure the research has been funded in open
national competition, appropriately peer-reviewed, is of
clear value to the NHS and fits within the needs and
realities of the NHS.
Researchers completing their approval forms within the
Integrated Research System (IRAS) can choose on the
first page of their IRAS application to have their project
assessed for CRN support and inclusion in the CRN
Portfolio. If you choose to be considered for portfolio
inclusion, you will be asked to complete and submit a
CRN portfolio application form (PAF). Only one PAF is
required for the entire research project from the lead site,
where the Chief Investigator is based. Within 2 working
days, you will receive confirmation that you can use the
Coordinated System for Gaining NHS Permission (CSP)
system through which you should complete and
submit your Research and Development (R&D)
application. The eligibility process runs in parallel to
the R&D checks and a decision on eligibly for the NIHR
Portfolio will then be given within 30 days. In 2013/14,
the median number of days to achieve NHS Permission
for all study sites for all portfolio studies was 25 calendar
days (http://www.crn.nihr.ac.uk/about-crn/our-perfor-
mance/key-statistics-2/).
Further information on the process can be found at:
http://www.crn.nihr.ac.uk/can-help/funders-academics/
gaining-nhs-permissions/the-csp-flowchart/).
Commercial studies
The CRN provides free support to help the life sciences
industry to deliver high-quality research in the NHS. The
CRN’s priority is to proactively support the life sciences
industry to deliver high-quality clinical research in the NHS,
and to enable this, they have developed a range of free
services and support tools around feasibility, set-up and
performance management.
To be eligible for inclusion on the portfolio, commercial
studies (i.e. those which are industry-led and either fully or
partly industry supported)must be submitted to the network
via an online system by a member of the sponsoring
company or Clinical Research Organisation (CRO) for the
assessment against the following eligibility criteria, as
defined by the Department of Health:
• The studymustmeet the networks definition of ‘research’
(further information can be found at the web link below).
• The study must receive NHS Research Ethics Committee
approval and NHS permission prior to initiation at
individual sites.
Researchers wishing to introduce commercial companies
to the network should direct them to thewebsite http://www.
crn.nihr.ac.uk/can-help/life-sciences-industry/. Companies
can submit their studies to the network at www.submitmy-
study.nihr.ac.uk.
Success story 1
Established in October 2007, the Chronic Rhinosinusitis
Epidemiology Study (CRES) was run in ENT departments in
East Anglia. The study set out to recruit 1000 patients with
chronic rhinosinusitis and 200 control subjects. The aimwas
to investigate the medical, socio-economic, psychological
and environmental factors that may influence the severity of
chronic rhinosinusitis and so address one of the research
objectives of the European Position Paper on Rhinosinusitis
and Nasal Polyps.1
From 2007 to 2012, a total of 627 participants were
recruited at a rate of about 7 per month. Following
appointment at the University of East Anglia as a Senior
Lecturer, Mr Carl Philpott (Eastern ENT local lead) used
funding from the Anthony Long Trust to establish this as a
study eligible for inclusion on the portfolio.
Adoption onto the portfolio inAugust 2012, together with
the support of the national ENT specialty, raised the profile
of this study enabling it to be expanded to numerous sites
throughout the United Kingdom (Fig. 2). The geographic
distribution of study participants included a wide range of
rural and urban areas of England and 2 of 3 devolved nations
(Fig. 3). CRN support included provision of funding for
research nurses or administrative input with the greatest
network input seen in the North East, resulting in recruit-
Fig. 2. Number of open recruitment sites in the Chronic Rhinos-
inusitis Epidemiology Study (CRES) following portfolio inclusion
in August 2012.
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ment of the highest number of participants outside of East
Anglia. Overall, the number of study participants entering
the study each month rose from the seven recruited in
September 2012 to a peak of 130 participants in August 2013
(Fig. 4).
With this successful UK-wide support, the study com-
pleted recruitment of 1552 participants in September 2013,
with 1480 complete data sets recorded in the final database.
Study data are currently being analysed at the University of
East Anglia and once published will provide further impetus
for research initiatives in rhinosinusitis in the United
Kingdom.
What is the NIHR ENT specialty?
‘Specialties’ were set up by the NIHR CRN to provide
national networks of topic-specific expertise. The aim of the
ENT specialty is to ensure the successful completion of
NIHR Portfolio research studies within ENT, hearing and
balance. Each specialty is formed of clinical researchers who
represent their local network and act as local leads. Each local
lead is able to provide guidance on the development and
conduct of research within their region. In addition, these
localmembers form a national network of expertise across all
areas of healthcare.
The ENT specialty currently has 11 local leads spanning
the United Kingdom with a wide range of subspecialty
expertise (Table 1). The member currently appointed as
national lead for the ENT specialty is Professor Anne
Schilder.
Local leads, together with additional members represent-
ing the devolved nations and important ENT stakeholders,
meet three times a year to discuss national ENT research and
the support they can provide to portfolio studies. For
example, they identify the portfolio studies that are strug-
gling to recruit participants and those that need to open up to
additional sites. In addition, the specialty is able to provide
detailed subspecialty clinical advice to researchers investi-
gating a specific condition/area within ENT. Local leads are
able to provide details of patient populations within
their region, so promoting study opening within new NHS
Trusts and enhancing the number of patients offered the
opportunity to participate in research across the United
Kingdom.
The ENT specialty works to engage the wider ENT
community in the work of the CRN to raise awareness of
the support the network provides. As a result, a coordinated
national message is being spread to researchers, ENT
research initiatives are starting to broaden from local
studies to multicentre trials, and the proportion of open
studies on the portfolio recruiting the required number of
participants within the timescale of the funding has
improved.
The ENT specialty has also organised successful workshop
sessions, open to the wider ENT community, with themes
such as Patient and Public Involvement (2012, 2014),
Working with Industry (2013) and Developing Research
Questions and Prioritisation in collaboration with NETSCC
2013).
Success story 2
The chief investigator of the Genetics of Otitis Media
study, Mr Mahmood Bhutta, believes the success of this
study is down to the network support he and his team
Fig. 3. Geographical spread of recruitment sites for the Chronic
Rhinosinusitis Epidemiology Study (CRES).
Fig. 4. Number of patients recruited to the Chronic Rhinosinusitis
Epidemiology Study (CRES) per month following portfolio inclu-
sion in August 2012.
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received. Otitis media is known to be highly heritable, and
his study set out to discover candidate genetic polymor-
phisms conferring susceptibility, through recruitment of
children having grommets inserted to treat chronic glue
ear.
Power calculations showed that at least 900 affected
families needed to be recruited to discover genes ofmoderate
relative risk, amounting to around 3500 individual partic-
ipants. The original plan was to recruit from eight regional
hospitals in the Thames Valley area, but early recruitment
was slow, and it transpired that unfortunately less than half
of participants who agreed to participate actually returned
their DNA.2 In the first 10 months of the study, an average of
only nine families per month were successfully recruited, a
trajectory that predicted that less than half of the recruitment
target would be reached in the 3–4 years allocated to this
study.
Inclusion onto the portfolio transformed the study
(Fig. 5). Funds were provided for a full-time research
nurse and a study administrator, and the study was
advertised through the NIHR Portfolio website. Contact
from research teams across the United Kingdom meant
the study rapidly expanded to include 36 centres (Fig. 6).
In the last 6 months of 2013, the study was recruiting an
average of 45 families per month. The study was extended
to recruit beyond the original sample size to enable
analysis of genotypes of lower relative risk and has now
recruited over 1600 families (around 6000 individuals) to
the end of 2013, making this also the largest study in the
world investigating the genetics of otitis media. That is all
down to the support afforded through the CRN.
Contact us
This article has outlined how the NIHR is supporting
clinical research in the NHS through infrastructure,
clinical networks and training. The success stories are
growing and the pace and quality of research within ENT
is increasing. To take advantage of the support and
delivery options available to researchers, we encourage
ENT researchers to contact the CRN via their local
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Fig. 5. Recruitment to the genetics of otitis media study April 2009 to December 2013.
Fig. 6. Recruitment sites for the genetics of otitismedia study April
2009 to December 2013.
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network, through the main NIHR CRN website, or via the
ENT specialty.
How do I approach the CRN?
• The NIHR CRN website http://www.crn.nihr.ac.uk/
• Your local network (LCRN) http://www.crn.nihr.ac.
uk/about_us
• The ENT specialty http://www.crn.nihr.ac.uk/abou-
t_us/ear_nose_throat/
• The national ENT specialty lead a.schilder@ucl.ac.uk
• The national ENT specialty administrator m.sim-
monds@ucl.ac.uk
• Your ENT specialty local lead (Table 1)
Keypoints
• TheNIHRCRN provides the infrastructure to support
clinical research in the NHS
• ENT researchers can accessCRN support by registering
their studies onto the CRN Portfolio
• Two recently completed ENT clinical studies have
attributed their success to the support they received
from the NIHR CRN
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